- Home
- PLX vs QTRX Comparison
PLX vs QTRX Comparison
Compare PLX & QTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- QTRX
- Stock Information
- Founded
- PLX 1993
- QTRX 2007
- Country
- PLX United States
- QTRX United States
- Employees
- PLX N/A
- QTRX N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- QTRX Biotechnology: Laboratory Analytical Instruments
- Sector
- PLX Health Care
- QTRX Industrials
- Exchange
- PLX Nasdaq
- QTRX Nasdaq
- Market Cap
- PLX 204.9M
- QTRX 241.2M
- IPO Year
- PLX 1998
- QTRX 2017
- Fundamental
- Price
- PLX $2.19
- QTRX $4.94
- Analyst Decision
- PLX Strong Buy
- QTRX Hold
- Analyst Count
- PLX 1
- QTRX 4
- Target Price
- PLX $15.00
- QTRX $11.75
- AVG Volume (30 Days)
- PLX 934.1K
- QTRX 508.1K
- Earning Date
- PLX 11-13-2025
- QTRX 11-10-2025
- Dividend Yield
- PLX N/A
- QTRX N/A
- EPS Growth
- PLX N/A
- QTRX N/A
- EPS
- PLX 0.08
- QTRX N/A
- Revenue
- PLX $61,948,000.00
- QTRX $125,784,000.00
- Revenue This Year
- PLX $14.53
- QTRX N/A
- Revenue Next Year
- PLX $75.77
- QTRX $37.03
- P/E Ratio
- PLX $28.28
- QTRX N/A
- Revenue Growth
- PLX 62.79
- QTRX N/A
- 52 Week Low
- PLX $1.16
- QTRX $4.05
- 52 Week High
- PLX $3.10
- QTRX $15.67
- Technical
- Relative Strength Index (RSI)
- PLX 46.99
- QTRX 37.62
- Support Level
- PLX $2.25
- QTRX $4.93
- Resistance Level
- PLX $2.40
- QTRX $5.46
- Average True Range (ATR)
- PLX 0.14
- QTRX 0.29
- MACD
- PLX -0.02
- QTRX -0.09
- Stochastic Oscillator
- PLX 40.70
- QTRX 7.09
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About QTRX Quanterix Corporation
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.